Would you offer immunotherapy after chemoradiotherapy for Stage III lung cancer given results of PACIFIC Trial?

In light of the comments by Professor Vansteenkinste comparing the ESMO 2017 plenary session incorporating the PACIFIC study results as a “tsunami” in the footsteps of last year’s ESMO lung cancer “earthquake” presentations, an appropriate title to this question might be- should we let the” floodgat...

Upon FDA approval I will offer durvalumab for my definitively chemoradiation treated stage III patients who have acceptable lung volume radiation dosing.

The trial population was "real world" with no restrictions on types of chemotherapy or planned radiation cycles provided the radiation dose was 54...